Compare Orchid Chemicals with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs SANOFI INDIA - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD SANOFI INDIA ORCHID PHARMA LTD/
SANOFI INDIA
 
P/E (TTM) x -0.5 36.1 - View Chart
P/BV x 0.1 6.3 1.9% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 ORCHID PHARMA LTD   SANOFI INDIA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
SANOFI INDIA
Dec-18
ORCHID PHARMA LTD/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1946,840 2.8%   
Low Rs354,630 0.8%   
Sales per share (Unadj.) Rs276.51,203.1 23.0%  
Earnings per share (Unadj.) Rs-79.2165.3 -47.9%  
Cash flow per share (Unadj.) Rs-43.5209.9 -20.7%  
Dividends per share (Unadj.) Rs084.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs53.9963.6 5.6%  
Shares outstanding (eoy) m70.4523.03 305.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.44.8 8.7%   
Avg P/E ratio x-1.434.7 -4.2%  
P/CF ratio (eoy) x-2.627.3 -9.6%  
Price / Book Value ratio x2.16.0 35.7%  
Dividend payout %050.8 0.0%   
Avg Mkt Cap Rs m8,067132,078 6.1%   
No. of employees `0002.83.3 84.8%   
Total wages/salary Rs m2,5274,068 62.1%   
Avg. sales/employee Rs Th6,956.18,393.8 82.9%   
Avg. wages/employee Rs Th902.51,232.4 73.2%   
Avg. net profit/employee Rs Th-1,993.01,153.0 -172.9%   
INCOME DATA
Net Sales Rs m19,47727,708 70.3%  
Other income Rs m407897 45.4%   
Total revenues Rs m19,88428,605 69.5%   
Gross profit Rs m1,1036,235 17.7%  
Depreciation Rs m2,5191,027 245.3%   
Interest Rs m5,2277 74,668.6%   
Profit before tax Rs m-6,2366,098 -102.3%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1252,292 -5.5%   
Profit after tax Rs m-5,5803,806 -146.6%  
Gross profit margin %5.722.5 25.2%  
Effective tax rate %2.037.6 5.3%   
Net profit margin %-28.713.7 -208.6%  
BALANCE SHEET DATA
Current assets Rs m11,01415,922 69.2%   
Current liabilities Rs m32,0606,235 514.2%   
Net working cap to sales %-108.135.0 -309.1%  
Current ratio x0.32.6 13.5%  
Inventory Days Days9564 149.1%  
Debtors Days Days3421 160.8%  
Net fixed assets Rs m29,4407,539 390.5%   
Share capital Rs m705230 306.3%   
"Free" reserves Rs m2,04321,962 9.3%   
Net worth Rs m3,80022,192 17.1%   
Long term debt Rs m9,0180-   
Total assets Rs m46,51029,839 155.9%  
Interest coverage x-0.2872.1 -0.0%   
Debt to equity ratio x2.40-  
Sales to assets ratio x0.40.9 45.1%   
Return on assets %-0.812.8 -5.9%  
Return on equity %-146.917.2 -856.3%  
Return on capital %-3.727.5 -13.6%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,5137,587 99.0%   
Fx outflow Rs m5,6497,145 79.1%   
Net fx Rs m1,865442 421.8%   
CASH FLOW
From Operations Rs m1,6823,739 45.0%  
From Investments Rs m-9,860-731 1,348.9%  
From Financial Activity Rs m6,644-1,972 -336.9%  
Net Cashflow Rs m-1,5351,036 -148.2%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 4.6 14.4 31.9%  
FIIs % 3.3 14.6 22.6%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 10.5 526.7%  
Shareholders   84,811 15,184 558.6%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  VENUS REMEDIES  IPCA LABS  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS